IMUX · XBRL financial data
Immunic financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (IMUX's year ends in late December)
- † Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (IMUX's year ends in late December)
- † Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (IMUX's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | †Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (22,769) | (21,572)* | (29,584) | (21,380) | (24,368) | (25,175)* | (25,473) | (26,820) | (25,579) | (19,300)* | (32,588) | (34,099) |
| Stock-based compensation | 1,687* | 1,638* | 2,750 | 1,882* | 1,910* | 1,985* | 2,042 | 1,899* | 3,614* | 1,308* | 4,466 | 6,782* |
| Depreciation and amortization | 34* | 23* | 26 | 31* | 42* | 35* | 43 | 43* | 40* | 42* | 33 | 34* |
| Net cash from operating activities | (17,312)* | (14,027)* | (23,969) | (17,031)* | (20,803)* | (22,963)* | (21,776) | (24,609)* | (20,140)* | (19,281)* | (17,301) | (30,998)* |
| Purchases of property and equipment | 44* | 165* | 31 | 180* | 50* | 3* | 47 | 36* | 67* | 11* | 2 | 249* |
| Net cash from investing activities | (44)* | (165)* | (31) | (180)* | (50)* | (3)* | (47) | (36)* | (67)* | (11)* | (2) | (249)* |
| Proceeds from issuing common stock | 282* | 571* | 191 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | — | — |
| Net cash from financing activities | 282* | 604* | 74,464 | 0* | 0* | 77* | 0 | 65,518* | 0* | 59* | 188,642 | 118* |
| Net change in cash | (17,605)* | (13,015)* | 50,638 | (17,614)* | (20,627)* | (23,403)* | (21,364) | 41,006* | (20,178)* | (19,649)* | 171,146 | (31,531)* |
- † Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.
Not investment advice. Not affiliated with the U.S. SEC.